ScholarIQanswers from OpenAlex & ORCID
Jacek Jassem
ResearcherPublications, citations & collaboration network
Jacek Jassem is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Jacek Jassem have?
ScholarIQindexed works
Jacek Jassem has 1,007 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Jacek Jassem have?
ScholarIQcitation count
Jacek Jassem has 56,564 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Jacek Jassem?
ScholarIQh-index
Jacek Jassem has an h-index of 87 in OpenAlex.
What is the i10-index of Jacek Jassem?
ScholarIQi10-index
Jacek Jassem has an i10-index of 348 in OpenAlex.
What is the ORCID of Jacek Jassem?
ScholarIQorcid
The ORCID for Jacek Jassem is on the source record.
What is the OpenAlex record for Jacek Jassem?
ScholarIQopenalex
The OpenAlex for Jacek Jassem is on the source record.
What are the most-cited papers on Jacek Jassem?
ScholarIQmost cited works
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
Aron Goldhirsch, Eric P. Winer, Alan S. Coates, Richard D. Gelber, Martine Piccart, Beat Thürlimann, Hans-Jörg Senn, Kathy S. Albain, Fabrice André, Jonas Bergh, Hervé Bonnefoi, Denisse Bretel-Morales, Harold J. Burstein, Fátima Cardoso, Monica Castiglione‐Gertsch, Alan S. Coates, Marco Colleoni, Alberto Costa, Giuseppe Curigliano, Nancy E. Davidson, Angelo Di Leo, Bent Ejlertsen, John Forbes, Richard D. Gelber, Michael Gnant, Aron Goldhirsch, Pamela J. Goodwin, Paul E. Goss, Jay R. Harris, Daniel F. Hayes, Clifford A. Hudis, James N. Ingle, Jacek Jassem, Zefei Jiang, Per Karlsson, Sibylle Loibl, Monica Morrow, Moïse Namer, C. Kent Osborne, Ann H. Partridge, Frédérique Penault‐Llorca, Charles M. Perou, Martine Piccart, Kathleen I. Pritchard, Emiel J. Rutgers, Felix Sedlmayer, Semiglazov Vf, Zhi‐Ming Shao, Ian Smith, Beat Thürlimann, Masakazu Toi, Andrew Tutt, Michael Untch, Giuseppe Viale, Toru Watanabe, Nicholas Wilcken, Eric P. Winer, William C. Wood
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
R. Charles Coombes, Emma Hall, Lorna J. Gibson, Robert Paridaens, Jacek Jassem, T. Delozier, Stephen E. Jones, Isabel Álvarez, Gianfilippo Bertelli, Olaf Ortmann, Alan S. Coates, Emilio Bajetta, David Dodwell, Robert E. Coleman, Lesley Fallowfield, E. Mickiewicz, Jørn Andersen, Per Eystein Lønning, Giorgio Cocconi, Alan L. Stewart, Nick Stuart, Claire Snowdon, M. Carpentieri, Giorgio Massimini, Judith M. Bliss
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
Roy S. Herbst, Giuseppe Giaccone, Filippo de Marinis, Niels Reinmuth, A. Vergnenègre, Carlos H. Barrios, Masahiro Morise, Enriqueta Felip, Zoran Andrić, Sarayut Lucien Geater, Mustafa Özgüroğlu, Wei Zou, Alan Sandler, Ida Enquist, Kimberly M. Komatsubara, Yu Deng, Hiroshi Kuriki, Xiaohui Wen, Mark L. McCleland, Simonetta Mocci, Jacek Jassem, David R. Spigel
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Giuseppe Curigliano, Harold J. Burstein, Eric P. Winer, Michael Gnant, Peter Dubsky, Sibylle Loibl, Marco Colleoni, Meredith M. Regan, Martine Piccart, Hans-Jörg Senn, Beat Thürlimann, Fabrice André, José Baselga, Jonas Bergh, Hervé Bonnefoi, Sara Y. Brucker, Fátima Cardoso, Lisa A. Carey, Eva Ciruelos, Jack Cuzick, Carsten Denkert, Angelo Di Leo, Bent Ejlertsen, Prudence A. Francis, V.E. Galimberti, Judy E. Garber, Bahadır M. Güllüoğlu, Pamela J. Goodwin, Nadia Harbeck, Daniel F. Hayes, Chiun‐Sheng Huang, Jens Huober, Hussein Khaled, Jacek Jassem, Zefei Jiang, Per Karlsson, Monica Morrow, Roberto Orecchia, Kent C. Osborne, Olivia Pagani, Ann H. Partridge, K. Pritchard, Jungsil Ro, Emiel J. Rutgers, Felix Sedlmayer, Semiglazov Vf, Zhi‐Ming Shao, Ian Smith, Masakazu Toi, Andrew Tutt, Giuseppe Viale, Toru Watanabe, Timothy J. Whelan, Binghe Xu
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
R. Charles Coombes, Lucy Kilburn, CF Snowdon, Robert Paridaens, RE Coleman, SE Jones, Jacek Jassem, CJH van de Velde, T. Delozier, Isabel Álvarez, Lucia Del Mastro, Olaf Ortmann, K. Diedrich, AS Coates, Emilio Bajetta, Holmberg Sb, David Dodwell, E. Mickiewicz, J. Andersen, Per Eystein Lønning, Giorgio Cocconi, John Forbes, M. Castiglione, N Stuart, A. Stewart, Lesley Fallowfield, Gianfilippo Bertelli, Emma Hall, Richard Bogle, M. Carpentieri, E Colajori, Milayna Subar, Elizabeth Ireland, Judith M. Bliss